亿帆医药：全资子公司合肥亿帆生物制药收到注射用盐酸表柔比星、注射用阿糖胞苷药品注册证书

Core Viewpoint - Yifan Pharmaceutical (002019) announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical received approval from the National Medical Products Administration for the registration certificates of injectable hydrochloride of gemcitabine and injectable cytarabine [1] Group 1: Product Approvals - The injectable hydrochloride of gemcitabine is indicated for the treatment of malignant lymphoma, breast cancer, and lung cancer, with an estimated domestic sales of approximately 456 million yuan in the first half of 2024 [1] - The injectable cytarabine is suitable for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children, with an estimated domestic sales of approximately 188 million yuan in the first half of 2024 [1] Group 2: R&D Investment - The company invested approximately 11.96 million yuan in the research and development of injectable hydrochloride of gemcitabine [1] - The company invested approximately 16.93 million yuan in the research and development of injectable cytarabine [1]